Drug Discovery & DDS– category –
-
AI-Powered In Silico Design Revolutionizes RNA-LNP Therapies for Targeted Delivery and CRISPR Gene Editing
InSilicoMinds USA Overview In silico (computational) design is fundamentally transforming the development of lipid nanoparticle (LNP) and RNA therapeutics by enabling the precise optimization of LNP properties for tissue-specific drug de... -
ADCs Take Center Stage at HerHealth2026: A Promising Strategy for Refractory Breast and Gynecological Cancers
HerHealth2026 USA Overview At the recent HerHealth2026 conference, Antibody-Drug Conjugates (ADCs) emerged as a pivotal topic, underscoring their growing importance in treating breast and gynecological cancers. These innovative therapies... -
Entera Bio’s Oral Peptide Platform Advances to Phase 3 for Osteoporosis, Heralding a New Era for Injectable Therapeutics
Entera Bio, Inc. USA Overview Clinical-stage biopharmaceutical company Entera Bio has secured an agreement with the FDA to initiate a Phase 3 clinical trial for EB613, an oral parathyroid hormone (PTH) analog for postmenopausal osteoporo... -
BioRay Pharmaceutical Advances Novel Dual-Payload TROP2 ADC, BR113, into First-in-Human Clinical Trials
AllSci China Overview China's BioRay Pharmaceutical has initiated a first-in-human Phase I trial for BR113, an innovative dual-payload TROP2 antibody-drug conjugate (ADC) targeting patients with advanced solid tumors. BR113 distinguishes... -
AsymBio Secures $184M to Scale Biologics CDMO Capacity for Advanced Therapies like ADCs and Bispecific Antibodies
Megaproject China Overview Shanghai-based biologics CDMO AsymBio has successfully raised approximately $184 million (1.24 billion RMB) from investors including Asymchem Group and Hillhouse Qirui. This substantial investment will drive th... -
Nanoparticle Breakthroughs: Piercing the Blood-Brain Barrier to Revolutionize CNS Disease Treatment, Including Glioblastoma
MDPI Switzerland Overview Nanoparticle-based drug delivery systems are emerging as a pivotal solution for overcoming the blood-brain barrier (BBB), a critical challenge in treating central nervous system (CNS) diseases. A recent review h... -
Unlocking mRNA LNP Design: Cholesterol Found Unnecessary for Non-Hepatic Delivery
ACS Nano USA Overview New research thoroughly dissects the functional roles of individual lipid components within mRNA lipid nanoparticles (LNPs), revealing that while ionizable lipids are critical for delivery efficacy, cholesterol is e... -
Next-Gen ADCs Show Transformative Efficacy: 46% ORR in Platinum-Resistant Gynecological Cancers, up to 50% ORR in Nasopharyngeal Cancer at AACR 2026
AACR Annual Meeting 2026 USA Overview The AACR Annual Meeting 2026 highlighted groundbreaking clinical results for next-generation Antibody-Drug Conjugates (ADCs), demonstrating significant advances in targeted cancer therapy. A combinat... -
Merck Ups 2026 Guidance on Strong Q2, KEYTRUDA Bladder Cancer Expansion, and ENFLONSIA RSV Indication Broadening Bolstering Investment Story
Simply Wall St USA Overview Merck achieved robust Q2 2026 performance and subsequently upgraded its full-year guidance, driven by key regulatory advancements. The company's investment narrative is significantly strengthened by the new bl... -
Recursion Pharmaceuticals Reports Q2 Revenue Pressure but Advances First AI-Designed Neuroscience Target with Genentech to Early Discovery
Simply Wall St USA Overview Recursion Pharmaceuticals (RXRX) reported Q2 2026 revenue pressures and ongoing losses but highlighted a significant milestone: its first neuroscience target, identified through its AI drug discovery platform ...
